NNC 0151-0000-0000
- Generic Name
- NNC 0151-0000-0000
Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects
Phase 1
Completed
- Conditions
- Systemic Lupus ErythematosusInflammationRheumatoid ArthritisHealthy
- Interventions
- Drug: placebo
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT02151409
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- InflammationRheumatoid Arthritis
- Interventions
- Drug: placebo
- First Posted Date
- 2010-10-19
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 34
- Registration Number
- NCT01223911
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Swansea, United Kingdom
An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)
Phase 1
Withdrawn
- Conditions
- InflammationSystemic Lupus Erythematosus
- Interventions
- Drug: placebo
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT01018238
- Locations
- 🇺🇸
Novo Nordisk Clinical Trial Call Center, Lake Success, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath